Maribavir

马立巴韦

Report date: 2026/05/22 20:01:29
NMEFirst In Class

Base Information

Drug NameMaribavir
Drug Alias Name马立巴韦BenzimidavirMaribavirumLivtencityGW-257406X +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA synthesis inhibitorsUL97 kinase inhibitors
TargetsUL97 kinase
Therapy Area/IndicationsHematologic NeoplasmsCytomegalovirus InfectionsHIV Infections
Global Approved IndicationsCytomegalovirus Infections
Approved Indications in ChinaCytomegalovirus Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2021/11/23
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdShireTakeda Pharmaceuticals USA Inc +[7] 
Inactive CompaniesShire Viropharma IncorporatedGlaxo Wellcome IncTakeda Ireland Ltd +[4] 
Active IndicationsHematologic NeoplasmsCytomegalovirus Infections
Inactive IndicationsHIV Infections

Other Information

ATC CodeJ05AX10
Related LinksWikipediaDrugBankKEGG